Stockscreener 앱 받기
0.6399
5.61%
0.034
시간 외 거래:
.63
-0.0099
-1.55%
전일 마감가:
$0.6059
열려 있는:
$0.5715
하루 거래량:
7.68M
Relative Volume:
1.67
시가총액:
$24.42M
수익:
-
순이익/손실:
$-117.67M
주가수익비율:
-0.2261
EPS:
-2.83
순현금흐름:
$-101.06M
1주 성능:
+31.23%
1개월 성능:
+50.56%
6개월 성능:
-67.35%
1년 성능:
-60.50%
1일 변동 폭
$0.5653
$0.6749
1주일 범위
$0.42
$0.7469
52주 변동 폭
$0.4115
$4.2984
Athira Pharma Inc Stock (ATHA) Company Profile
명칭
Athira Pharma Inc
전화
(425) 620-8501
주소
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-10-17 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-06-23 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-06-23 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-06-23 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-05-10 | 개시 | BTIG Research | Buy |
| 2022-04-21 | 개시 | Berenberg | Buy |
| 2021-12-15 | 개시 | Goldman | Neutral |
| 2020-10-13 | 개시 | Goldman | Buy |
| 2020-10-13 | 개시 | JMP Securities | Mkt Outperform |
| 2020-10-13 | 개시 | Jefferies | Buy |
| 2020-10-13 | 개시 | Stifel | Buy |
모두보기
Athira Pharma Inc 주식(ATHA)의 최신 뉴스
Errors Lower Fee Award For Athira Pharma Investors' Counsel - Law360
US Penny Stocks: November 2024's Top Picks To Consider - Simply Wall St
Perceptive Advisors LLC Acquires Significant Stake in Athira Pha - GuruFocus.com
ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal - MSN
Athira Pharma to Present Results from Phase 2/3 LIFT-AD - GlobeNewswire
Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting - StockTitan
Athira Pharma faces Nasdaq delisting over share price - Investing.com
A closer look at Athira Pharma Inc (ATHA)’s stock price trends - US Post News
A year in review: Athira Pharma Inc (ATHA)’s performance in the last year - US Post News
A Guide To The Risks Of Investing In Athira Pharma Inc (ATHA) - Knox Daily
Analytical Overview: Athira Pharma Inc (ATHA)’s Ratios Tell a Financial Story - The Dwinnex
Athira Pharma, Inc. (NASDAQ:ATHA) Shares Bought by Forefront Analytics LLC - Defense World
Wall Street SWOT: Athira Pharma stock faces crossroads after Alzheimer's trial setback - Investing.com
Athira Pharma Inc (ATHA) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Athira Pharma stock plunges to 52-week low of $0.41 - Investing.com
Athira Pharma stock plunges to 52-week low of $0.41 By Investing.com - Investing.com Canada
Taking a look at what insiders are doing to gauge the Athira Pharma Inc (ATHA)’s direction - Knox Daily
Check out these key findings about Athira Pharma Inc (ATHA) - SETE News
Was Athira Pharma Inc (ATHA)’s session last reading good? - US Post News
Athira Pharma to lay off 70% of workforce - PharmaLive
Athira Pharma Inc (ATHA) Becoming More Attractive for Investors - Knox Daily
Market Watch Highlights: Athira Pharma Inc (ATHA) Ends on an Downturn Note at 0.43 - The Dwinnex
Athira Pharma to Lay Off 70% of Workforce - BioSpace
After Alzheimer's stumble, Athira lays off 70% of workforce and pivots to ALS small molecule - Fierce Biotech
Athira Pharma stock faces pivot and workforce cuts amid trial setbackMizuho - Investing.com Canada
Athira Pharma Inc [ATHA] Officer makes an insider purchase of 5,032 shares worth 1.0. - Knox Daily
Athira Pharma stock hits 52-week low at $0.46 amid market challenges - Investing.com
Athira Pharma downgraded to Neutral from Outperform at Mizuho - TipRanks
Alterity Therapeutics Limited (NASDAQ:ATHE) Short Interest Down 8.7% in August - Defense World
Taking the lead: Athira Pharma Inc (ATHA) - SETE News
Athira Pharma Inc Inc. (ATHA) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Athira Pharma Inc (NASDAQ: ATHA): Slumped -75.09% In 2024, Outlook Stable - Stocks Register
Athira shifts focus to ALS drug after Alzheimer’s flop - The Pharma Letter
Athira Pharma lays off 70% of its staff as company shifts focus - The Business Journals
Athira Pharma to Cut About 70% of Workforce - MarketWatch
Athira Pharma to focus on ATH-1105 advancement, reduces workforce by 70% - TipRanks
Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring - GeekWire
Athira’s Alzheimer’s Drug Fails in Later-stage Clinical Trial - Being Patient
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases - GlobeNewswire
Market Recap Check: Athira Pharma Inc (ATHA)’s Negative Finish at 0.51, Up/Down -4.18 - The Dwinnex
Is Athira Pharma Inc (ATHA) a opportunity to investors? - US Post News
Athira Pharma Inc [ATHA] Investment Guide: What You Need to Know - Knox Daily
Market Update: Athira Pharma Inc (ATHA) Sees Positive Movement, Closing at 0.51 - The Dwinnex
AdPha urges HTA reform - Pharmacy Daily
Fosgonimeton fails to meet goal in Alzheimer’s clinical trial: Data - Alzheimer's News Today
Athira Pharma stock plunges to 52-week low of $0.46 By Investing.com - Investing.com Australia
Ready to Jump After Recent Trade: Athira Pharma Inc (ATHA) - SETE News
Athira Pharma stock plunges to 52-week low of $0.46 - Investing.com
Rodman & Renshaw downgrades Athira Pharma Inc (ATHA) rating to a Neutral - Knox Daily
ATHA’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Recent Insider Activity Suggests Potential Gains for Athira Pharma Inc (ATHA) - Knox Daily
Athira Pharma Inc (ATHA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.11%
0.50%
자본화:
|
볼륨(24시간):